Testing a New Imaging Method (68Ga-Pentixafor PET/CT) to Find Residual Multiple Myeloma After Treatment

Prospective Study to evaluate the Role of a Novel Imaging Study - 68 Ga PENtixafor PET/CT to Detect Residual Disease in Multiple Myeloma - ProPEN

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/04/108288

Enrollment

Registered

2026-04-13

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C900- Multiple myeloma

Interventions

Intervention1: 68Ga Pentixafor PET/CT: 68Ga Pentixafor PET/CT is a type of novel PET scan, that will be performed on all eligible and consenting patients at baseline and at three time points during th

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age, 18 years or above 2.Patients undergoing ASCT in first remission 3.Patients in at least VGPR and CR prior to ASCT 4.Transplant ineligible patients with VGPR and CR after 4 cycles and 8 cycles of chemotherapy

Exclusion criteria

Exclusion criteria: 1.Patients not undergoing baseline 18F FDG PET/CT scan 2.Pregnancy and lactation

Design outcomes

Primary

Measure	Time frame
To find out the concordance and discordance pattern of 18F FDG PET/CT and 68Ga Pentixafor PET/CT scan findings at various times points during the treatment of both transplant eligible and non eligible multiple myeloma patientsTimepoint: Baseline (T0), before autologus stem cell transplant (ASCT)(T1), day 100 from ASCT(T2), 1 year from T2 time point	—

Secondary

Measure	Time frame
1.To correlate 18F FDG PET/CT & 68Ga Pentixafor PET/CT findings with corresponding serological response & bone marrow MRD done at various time points 2.To look for 1 year progression free survival(PFS) & Time To Next Treatment & correlate with 18F FDG PET/CT & 68Ga Pentixafor PET/CT findings Timepoint: Baseline (T0), before autologus stem cell transplant (ASCT)(T1), day 100 from ASCT(T2), 1 year from T2 time point	—

Measure

Time frame

1.To correlate 18F FDG PET/CT & 68Ga Pentixafor PET/CT findings with corresponding serological response & bone marrow MRD done at various time points 2.To look for 1 year progression free survival(PFS) & Time To Next Treatment & correlate with 18F FDG PET/CT & 68Ga Pentixafor PET/CT findings Timepoint: Baseline (T0), before autologus stem cell transplant (ASCT)(T1), day 100 from ASCT(T2), 1 year from T2 time point

—

Countries

India

Contacts

Public ContactSayak Choudhury

Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)

choudhurysayak91@gmail.com7738714626

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026